Precigen, Inc. (PGEN)
- Previous Close
0.8345 - Open
0.8500 - Bid 0.8662 x 300
- Ask 0.9295 x 500
- Day's Range
0.8248 - 0.9022 - 52 Week Range
0.8200 - 1.9300 - Volume
506,656 - Avg. Volume
1,011,064 - Market Cap (intraday)
262.968M - Beta (5Y Monthly) 1.66
- PE Ratio (TTM)
-- - EPS (TTM)
-0.5400 - Earnings Date Nov 7, 2024 - Nov 11, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
6.00
Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ? trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.
precigen.comRecent News: PGEN
View MorePerformance Overview: PGEN
Trailing total returns as of 10/11/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PGEN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PGEN
View MoreValuation Measures
Market Cap
262.97M
Enterprise Value
249.77M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
51.14
Price/Book (mrq)
6.09
Enterprise Value/Revenue
56.91
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-42.32%
Return on Equity (ttm)
-129.32%
Revenue (ttm)
4.39M
Net Income Avi to Common (ttm)
-135.38M
Diluted EPS (ttm)
-0.5400
Balance Sheet and Cash Flow
Total Cash (mrq)
19.54M
Total Debt/Equity (mrq)
14.69%
Levered Free Cash Flow (ttm)
-45.84M
Research Analysis: PGEN
View MoreCompany Insights: PGEN
PGEN does not have Company Insights